Moberg Pharma: Interim report April - June 2020 |
| August 11, 2020 | August 2020 Bond Updates |
|
STOCKHOLM, Aug. 11, 2020 /PRNewswire/ -- The Primary endpoint was met in the Phase 3 study TWELVE MONTH PERIOD (JUL 2019-JUN 2020) Net revenue SEK 50.5 million (15.6) * EBITDA SEK 29.0 million (-3.0) * Operating profit (EBIT) SEK 26.4 million (-4.2) * Profit after tax SEK 20.0 million (-4.... |
| View more at: https://www.prnewswire.com:443/news-releases/moberg-pharma-interim-report-april---june-2020-301109659.html |
| Related News |
|